News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Release: Data Show That the Combination of Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia in Type 1 and Type 2 Diabetes Patients



12/6/2011 12:00:26 PM

DUBAI, United Arab Emirates--(BUSINESS WIRE)--A soluble co-formulation of insulin degludec and insulin aspart (IDegAsp) was associated with a 58% lower rate of confirmed hypoglycaemic episodes in people with type 2 diabetes compared to biphasic insulin aspart 30 (BIAsp 30) when dosed twice-daily. This is according to a study released today by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress.

Read at BioSpace.com


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES